Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes
Open Access
- 11 March 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (5) , 1228
Abstract
Dipeptidyl peptidase-4 (DPP-4) is a well-known therapeutic drug target proven to reduce blood glucose levels in diabetes mellitus, and clinically, DPP-4 inhibitors are used in combination with other anti-diabetic agents. However, side effects and skeletal muscle health are not considered in the treatment for diabetic patients. Recently, natural compounds have been proven to inhibit DPP-4 with fewer side effects. In this work, initially, molecular docking simulations revealed that a natural compound, Galangin, possess a binding energy of −24 KJ/mol and interaction residues SER 630 and TYR 547, that are responsible for potent DPP-4 inhibition. In vitro studies showed that galangin not only inhibits DPP-4 in a concentration-dependent manner but also regulates glucose levels, enabling the proliferation of rat L6 skeletal muscle cells. The combination of galangin with insulin benefits regulation of glucose levels significantly in comparison to galangin alone (p < 0.05). These findings suggest the beneficial effect of the use of galangin, both alone or in combination with insulin, to reduce glucose levels and improve skeletal muscle health in diabetes mellitus.Keywords
This publication has 41 references indexed in Scilit:
- Polyphenols: Benefits to the Cardiovascular System in Health and in AgingNutrients, 2013
- Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case seriesJournal of Medical Case Reports, 2011
- Inhibition of influenza virus replication by plant-derived isoquercetinAntiviral Research, 2010
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trialsNutrition, Metabolism and Cardiovascular Diseases, 2010
- Medicinal Chemistry of Incretin Mimetics and DPP‐4 InhibitorsChemMedChem, 2010
- Incretin-based therapies for type 2 diabetes mellitusNature Reviews Endocrinology, 2009
- 3D-QSAR studies of Dipeptidyl peptidase IV inhibitors using a docking based alignmentJournal of Molecular Modeling, 2007
- Incretins and other peptides in the treatment of diabetesDiabetic Medicine, 2007
- The Protein Data BankActa Crystallographica Section D Structural Biology, 2002
- Natural Products in Drug Discovery and DevelopmentJournal of Natural Products, 1997